Anaemia characterises patients with myelofibrosis harbouring Mpl mutation

Br J Haematol. 2007 May;137(3):244-7. doi: 10.1111/j.1365-2141.2007.06565.x.

Abstract

The clinical and haematological phenotype of patients with myelofibrosis harbouring MPL(W515L/K) mutation has not been thoroughly investigated. Of 217 myelofibrosis subjects, 18 (8.2%) had an MPL mutation, four of which (22%) co-existed with JAK2(V617F) mutation. When compared with MPL wild-type patients, irrespective of JAK2(V617F) status, those with MPL(W515L/K), were more frequently female, were older (61 years vs. 57 years; P = 0.02), presented with more severe anaemia (haemoglobin, 101 g/l vs. 121 g/l; P = 0.002) and were more likely to require regular transfusional support (P = 0.012). These data indicate that MPL mutation in myelofibrosis characterises patients with more severe anaemic phenotype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anemia / complications
  • Anemia / genetics*
  • Blood Transfusion
  • Erythropoiesis / physiology
  • Female
  • Genotype
  • Hemoglobins / analysis
  • Humans
  • Janus Kinase 2 / genetics
  • Male
  • Middle Aged
  • Mutation
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / therapy
  • Receptors, Thrombopoietin / genetics*
  • Sex Factors

Substances

  • Hemoglobins
  • Receptors, Thrombopoietin
  • MPL protein, human
  • JAK2 protein, human
  • Janus Kinase 2